AI assistant
Sending…
Tharimmune, Inc. — Director's Dealing 2023
May 15, 2023
34824_dirs_2023-05-15_26863c73-6f9d-4ca9-921b-03c6b67d956e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2023-05-09
Reporting Person: Anderson Kelly (Director)
More from Tharimmune, Inc.
Interim / Quarterly Report
2026
May 13
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Feb 18
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11